All Relations between Alzheimer Disease and microtubule-associated protein tau

Publication Sentence Publish Date Extraction Date Species
Adam S Fleisher, Leanne M Munsie, David G S Perahia, Scott W Andersen, Ixavier A Higgins, Paula M Hauck, Albert C Lo, John R Sims, Miroslaw Brys, Mark Mintu. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology. vol 102. issue 5. 2024-02-22. PMID:38386949. zagotenemab (ly3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the periscope-alz phase 2 study to determine its ability to slow cognitive and functional decline relative to placebo in early symptomatic alzheimer disease (ad). 2024-02-22 2024-02-25 Not clear
Withsakorn Sangsuwan, Kriangsak Faikhruea, Kotchakorn Supabowornsathit, Don Sangsopon, Praewphan Ingrungruanglert, Hathaichanok Chuntakaruk, Napatsaporn Nuntavanotayan, Kittiporn Nakprasit, Nipan Israsena, Thanyada Rungrotmongkol, Pitak Chuawong, Tirayut Vilaivan, Chanat Aonbangkhe. Design, Synthesis, and Characterization of Novel Styryl Dyes as Fluorescent Probes for Tau Aggregate Detection in Vitro and in Cells. Chemistry, an Asian journal. 2024-02-20. PMID:38377056. this work offers novel and non-cytotoxic fluorescent probes with desirable photophysical properties, which could potentially be used for studying tau aggregates in living cells, prompting further development of new fluorescent probes for early alzheimer's disease detection. 2024-02-20 2024-02-23 Not clear
Vaishnavi S Jadhav, Jade G Stair, Randall J Eck, Samuel N Smukowski, Heather N Currey, Laura Garcia Toscano, Joshua C Hincks, Caitlin S Latimer, Paul N Valdmanis, Brian C Kraemer, Nicole F Liachk. Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets. Neurobiology of disease. 2024-02-20. PMID:38378122. alzheimer's disease (ad), the most common aging-associated neurodegenerative dementia disorder, is defined by the presence of amyloid beta (aβ) and tau aggregates in the brain. 2024-02-20 2024-02-23 caenorhabditis_elegans
Abrar Younas, Neelam Younas, Muhammad Javed Iqbal, Isidre Ferrer, Inga Zer. Comparative interactome mapping of Tau-protein in classical and rapidly progressive Alzheimer's disease identifies subtype-specific pathways. Neuropathology and applied neurobiology. vol 50. issue 1. 2024-02-20. PMID:38374702. tau is a key player in alzheimer's disease (ad) and other tauopathies. 2024-02-20 2024-02-22 Not clear
Rebecca Beardmore, Matthew Durkin, Faizan Zayee-Mellick, Laurie C Lau, James A R Nicoll, Clive Holmes, Delphine Boch. Changes in the locus coeruleus during the course of Alzheimer's disease and their relationship to cortical pathology. Neuropathology and applied neurobiology. vol 50. issue 1. 2024-02-20. PMID:38374720. in alzheimer's disease (ad), the locus coeruleus (lc) undergoes early and extensive neuronal loss, preceded by abnormal intracellular tau aggregation, decades before the onset of clinical disease. 2024-02-20 2024-02-22 human
A C Macedo, D F P A Durço, C Tissot, J Therriault, A O Vilela de Faria, É Aumont, S Servaes, N Rahmouni, J Fernandez-Arias, Y-T Wang, F Z Lussier, A Bieger, E R Zimmer, T A Pascoal, S Gauthier, P Rosa-Net. Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease. The journal of prevention of Alzheimer's disease. vol 11. issue 2. 2024-02-20. PMID:38374747. however, the agreement between clinical and pathological alzheimer's disease diagnosis, whose diagnosis assessment includes amyloid and braak histopathological tau staging, is not completely convergent. 2024-02-20 2024-02-22 Not clear
A C Macedo, D F P A Durço, C Tissot, J Therriault, A O Vilela de Faria, É Aumont, S Servaes, N Rahmouni, J Fernandez-Arias, Y-T Wang, F Z Lussier, A Bieger, E R Zimmer, T A Pascoal, S Gauthier, P Rosa-Net. Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease. The journal of prevention of Alzheimer's disease. vol 11. issue 2. 2024-02-20. PMID:38374747. in line with this, there is a trend for unimpaired cognition, mild cognitive impairment, and alzheimer's disease dementia to be compatible with early, intermediate, and late patterns of tau deposition based on pet-based braak stages. 2024-02-20 2024-02-22 Not clear
A C Macedo, D F P A Durço, C Tissot, J Therriault, A O Vilela de Faria, É Aumont, S Servaes, N Rahmouni, J Fernandez-Arias, Y-T Wang, F Z Lussier, A Bieger, E R Zimmer, T A Pascoal, S Gauthier, P Rosa-Net. Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease. The journal of prevention of Alzheimer's disease. vol 11. issue 2. 2024-02-20. PMID:38374747. in sum, this framework seems to correspond well with the clinical progression of alzheimer's disease, which is an indication of its potential utility in research and clinical practice, especially for detecting preclinical tau levels in individuals without symptoms. 2024-02-20 2024-02-22 Not clear
D-Y Liu, L Zhan. Retraction Note: MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease. European review for medical and pharmacological sciences. vol 28. issue 3. 2024-02-20. PMID:38375693. retraction note: microrna-132 promotes neurons cell apoptosis and activates tau phosphorylation by targeting gtdc-1 in alzheimer's disease. 2024-02-20 2024-02-22 Not clear
D-Y Liu, L Zhan. Retraction Note: MicroRNA-132 promotes neurons cell apoptosis and activates Tau phosphorylation by targeting GTDC-1 in Alzheimer's disease. European review for medical and pharmacological sciences. vol 28. issue 3. 2024-02-20. PMID:38375693. the article "microrna-132 promotes neurons cell apoptosis and activates tau phosphorylation by targeting gtdc-1 in alzheimer's disease", by d.-y. 2024-02-20 2024-02-22 Not clear
Devin Wahl, Sydney J Risen, Shelby C Osburn, Tobias Emge, Sadhana Sharma, Vincenzo S Gilberto, Anushree Chatterjee, Prashant Nagpal, Julie A Moreno, Thomas J LaRocc. Nanoligomers targeting NF-κB and NLRP3 reduce neuroinflammation and improve cognitive function with aging and tauopathy. bioRxiv : the preprint server for biology. 2024-02-19. PMID:38370618. neuroinflammation contributes to impaired cognitive function in brain aging and neurodegenerative disorders like alzheimer's disease, which is characterized by the aggregation of pathological tau. 2024-02-19 2024-02-21 mouse
Kamila Sofińska, Sara Seweryn, Katarzyna Skirlińska-Nosek, Jakub Barbasz, Ewelina Lipie. Tip-enhanced Raman spectroscopy reveals the structural rearrangements of tau protein aggregates at the growth phase. Nanoscale. 2024-02-19. PMID:38372161. tau protein aggregates inside neurons in the course of alzheimer's disease (ad). 2024-02-19 2024-02-21 Not clear
Bryan Ng, Jane Vowles, Féodora Bertherat, Ajantha Abey, Peter Kilfeather, Dayne Beccano-Kelly, M Irina Stefana, Darragh P O'Brien, Nora Bengoa-Vergniory, Phillippa J Carling, John A Todd, Tara M Caffrey, Natalie Connor-Robson, Sally A Cowley, Richard Wade-Martin. Tau depletion in human neurons mitigates Aβ-driven toxicity. Molecular psychiatry. 2024-02-16. PMID:38361127. alzheimer's disease (ad) is an age-related neurodegenerative condition and the most common type of dementia, characterised by pathological accumulation of extracellular plaques and intracellular neurofibrillary tangles that mainly consist of amyloid-β (aβ) and hyperphosphorylated tau aggregates, respectively. 2024-02-16 2024-02-18 mouse
Nicolas De Leiris, Pascale Perret, Charlotte Lombardi, Bülent Gözel, Sabine Chierici, Philippe Millet, Marlène Debiossat, Sandrine Bacot, Benjamin B Tournier, Patrick Chames, Jean-Luc Lenormand, Catherine Ghezzi, Daniel Fagret, Marcelle Mouli. A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization. Journal of translational medicine. vol 22. issue 1. 2024-02-16. PMID:38365700. soluble oligomeric forms of tau protein have emerged as crucial players in the propagation of tau pathology in alzheimer's disease (ad). 2024-02-16 2024-02-19 human
Juan Lantero-Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu-Gaya, Wagner S Brum, Andrea L Benedet, Niklas Mattsson-Carlgren, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Oskar Hansso. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Molecular neurodegeneration. vol 19. issue 1. 2024-02-16. PMID:38365825. plasma n-terminal containing tau fragments (nta-tau): a biomarker of tau deposition in alzheimer's disease. 2024-02-16 2024-02-19 Not clear
Juan Lantero-Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu-Gaya, Wagner S Brum, Andrea L Benedet, Niklas Mattsson-Carlgren, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Oskar Hansso. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Molecular neurodegeneration. vol 19. issue 1. 2024-02-16. PMID:38365825. novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for alzheimer's disease (ad), and can track amyloid-β (aβ) and tau pathology. 2024-02-16 2024-02-19 Not clear
Bianca A Trombetta, Chao-Yi Wu, Evan Kuo, Matthijs B de Geus, Hiroko H Dodge, Becky C Carlyle, Pia Kivisäkk, Steven E Arnol. Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). vol 10. issue 1. 2024-02-15. PMID:38356471. while alzheimer's disease (ad) is defined by amyloid-β plaques and tau tangles in the brain, it is evident that many other pathophysiological processes such as inflammation, neurovascular dysfunction, oxidative stress, and metabolic derangements also contribute to the disease process and that varying contributions of these pathways may reflect the heterogeneity of ad. 2024-02-15 2024-02-17 Not clear
Pranitha Y Premnath, Joseph J Locascio, Kayden J Mimmack, Christopher Gonzalez, Michael J Properzi, Onyinye Udeogu, Paul B Rosenberg, Gad A Marshall, Jennifer R Gatche. Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & dementia (New York, N. Y.). vol 10. issue 1. 2024-02-15. PMID:38356477. longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: findings from the alzheimer's disease neuroimaging initiative. 2024-02-15 2024-02-17 Not clear
Pranitha Y Premnath, Joseph J Locascio, Kayden J Mimmack, Christopher Gonzalez, Michael J Properzi, Onyinye Udeogu, Paul B Rosenberg, Gad A Marshall, Jennifer R Gatche. Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & dementia (New York, N. Y.). vol 10. issue 1. 2024-02-15. PMID:38356477. in the current study, we sought to examine the relationships between longitudinal apathy and regional tau burden in cognitively impaired older adults from the alzheimer's disease neuroimaging initiative (adni) database. 2024-02-15 2024-02-17 Not clear
Ellie I James, David W Baggett, Edcon Chang, Joel Schachter, Thomas Nixey, Karoline Choi, Miklos Guttman, Abhinav Nat. Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation. bioRxiv : the preprint server for biology. 2024-02-14. PMID:38352474. microtubule-associated protein tau is an intrinsically disordered protein (idp) that forms characteristic fibrillar aggregates in several diseases, the most well-known of which is alzheimer's disease (ad). 2024-02-14 2024-02-16 Not clear